Expressions of matrix metalloproteinase 9 and tissue inhibitor of metalloproteinases 1 in lung tissues of neonatal rats with intrauterine infection

Objective: To investigate the changes and mechanisms of matrix metallopeptidase 9 (MMP-9) and tissue inhibitor of metalloproteinases 1 (TIMP-1) in the lung tissues of neonatal rats with intrauterine infection (II). Methods: The pregnant rats were divided into the intrauterine infection group (group LPS) and the control group (group NS). The rats in group LPS were intraperitoneally injected lipopolysaccharide (LPS) to establish the II animal model; the neonatal rats of the two groups were selected on D1, D3, D7, and D14 after birth for the HE staining and radiation alveolar count (RAC); meanwhile, the protein expression and mRNA quantification of MMP-9 and TIMP-1 in the lung tissues were detected. Results: Group LPS showed significantly increased infiltration of alveolar inflammatory cells and decreased RAC than group NS. The protein and mRNA expressions of MMP-9 in group LPS were significantly higher than group NS on D3, D7, and D14, and those expressions in group LPS showed no significant difference. The protein and mRNA expressions of TIMP-1 in group LPS were gradually increased after birth, and showed significant difference with group NS on D3, D7, and D14. Conclusions: The post-II expressions of MMP-9 and TIMP-1 in the lung tissues of the neonatal rats were significantly increased, and its imbalance might play an important role in repairing lung injuries and abnormalities.

[1]  A. Dufour.  Degradomics of matrix metalloproteinases in inflammatory diseases. , 2015, Frontiers in bioscience.

[2]  W. Rom,et al.  MMP-2 and TIMP-1 predict healing of WTC-lung injury in New York City firefighters , 2014, Respiratory Research.

[3]  Neil Marlow,et al.  Short term outcomes after extreme preterm birth in England: comparison of two birth cohorts in 1995 and 2006 (the EPICure studies) , 2012, BMJ : British Medical Journal.

[4]  P. E. Van den Steen,et al.  Targeting matrix metalloproteinases in acute inflammatory shock syndromes. , 2012, Combinatorial chemistry & high throughput screening.

[5]  R. Viscardi.  Perinatal inflammation and lung injury. , 2012, Seminars in fetal & neonatal medicine.

[6]  L. Hartling,et al.  Chorioamnionitis as a risk factor for bronchopulmonary dysplasia: a systematic review and meta-analysis , 2011, Archives of Disease in Childhood: Fetal and Neonatal Edition.

[7]  R. Homer,et al.  A role for matrix metalloproteinase 9 in IFNγ-mediated injury in developing lungs: relevance to bronchopulmonary dysplasia. , 2011, American journal of respiratory cell and molecular biology.

[8]  A. Jobe.  The new bronchopulmonary dysplasia , 2011, Current opinion in pediatrics.

[9]  X. Puente,et al.  Absence or inhibition of matrix metalloproteinase-8 decreases ventilator-induced lung injury. , 2010, American journal of respiratory cell and molecular biology.

[10]  D. Deming,et al.  The 'new' bronchopulmonary dysplasia: challenges and commentary. , 2009, Seminars in fetal & neonatal medicine.

[11]  F. Pirrone,et al.  In vivo study of the behaviour of matrix metalloproteinases (MMP-2, MMP-9) in mechanical, hypoxic and septic-induced acute lung injury , 2009, Veterinary Research Communications.

[12]  N. Sugino,et al.  MMP‐9 and TIMP‐1 in the cord blood of premature infants developing BPD , 2009, Pediatric pulmonology.

[13]  P. Ascenzi,et al.  Structural bases for substrate and inhibitor recognition by matrix metalloproteinases. , 2008, Current medicinal chemistry.

[14]  Xindong Xue,et al.  [The changes and effects of metalloproteinase-2 and tissue inhibitors of metalloproteinase-1 protein and mRNA expression in the lung tissue of neonatal rats with chronic lung disease induced by hyperoxia]. , 2008, Zhongguo wei zhong bing ji jiu yi xue = Chinese critical care medicine = Zhongguo weizhongbing jijiuyixue.

[15]  B. Thébaud,et al.  Bronchopulmonary dysplasia: where have all the vessels gone? Roles of angiogenic growth factors in chronic lung disease. , 2007, American journal of respiratory and critical care medicine.

[16]  P. Burri,et al.  Structural Aspects of Postnatal Lung Development – Alveolar Formation and Growth , 2006, Neonatology.

[17]  June-Dong Park,et al.  Risk factors for the different types of chronic lung diseases of prematurity according to the preceding respiratory distress syndrome , 2005, Pediatrics international : official journal of the Japan Pediatric Society.

[18]  W. Truog,et al.  Low levels of tissue inhibitors of metalloproteinases with a high matrix metalloproteinase-9/tissue inhibitor of metalloproteinase-1 ratio are present in tracheal aspirate fluids of infants who develop chronic lung disease. , 2004, Pediatrics.

[19]  V. Lagente,et al.  Imbalance between matrix metalloproteinases (MMP-9 and MMP-2) and tissue inhibitors of metalloproteinases (TIMP-1 and TIMP-2) in acute respiratory distress syndrome patients , 2003, Critical care medicine.

[20]  J. Fowlkes,et al.  Metalloproteinase and growth factor interactions: do they play a role in pulmonary fibrosis? , 2002, American journal of physiology. Lung cellular and molecular physiology.

[21]  Z. Werb,et al.  Signaling through the EGF receptor controls lung morphogenesis in part by regulating MT1-MMP-mediated activation of gelatinase A/MMP2. , 2002, Journal of cell science.

[22]  S. Shapiro,et al.  Matrix metalloproteinases in lung biology , 2000, Respiratory research.

[23]  J. Iams,et al.  Prevention of preterm birth. , 1988, Seminars in perinatology.

[24]  S. Conway,et al.  Aberrant signaling pathways of the lung mesenchyme and their contributions to the pathogenesis of bronchopulmonary dysplasia. , 2012, Birth defects research. Part A, Clinical and molecular teratology.

[25]  L. Monte,et al.  [Bronchopulmonary dysplasia]. , 2005, Jornal de pediatria.

[26]  W. Dik,et al.  Localization and Potential Role of Matrix Metalloproteinase-1 and Tissue Inhibitors of Metalloproteinase-1 and -2 in Different Phases of Bronchopulmonary Dysplasia , 2001, Pediatric Research.